Filtered By:
Condition: Heart Failure
Vaccination: Vaccines

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 45 results found since Jan 2013.

Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65  years or older: a nationwide population-based cohort study
ConclusionsCompared with the unvaccinated ICU survivors, the influenza vaccinated ICU survivors had a lower 1-year risk of stroke and a lower 1-year risk of death, whereas no substantial association was observed for the risk of hospitalization for myocardial infarction, heart failure, or pneumonia. Our findings support influenza vaccination of individuals aged  ≥ 65 years.
Source: Intensive Care Medicine - June 10, 2019 Category: Intensive Care Source Type: research

Flu vaccine reduces risk of hospital stay for stroke, heart failure for diabetes patients
People with type 2 diabetes who receive the influenza vaccine may be less likely to be admitted to hospital for myocardial infarction, stroke and heart failure, according to new research.
Source: ScienceDaily Headlines - July 25, 2016 Category: Science Source Type: news

Beneficial Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart Failure
Influenza and pneumococcal infections have been suggested to be potential risk factors for causing adverse cardiovascular events, especially in high-risk patients. Vaccination against respiratory infections in patients with established cardiovascular disease (CVD) could serve as a potential cost-effective intervention to improve their clinical outcomes and cardiac societies have encouraged it. Previous studies have shown that influenza vaccination reduce mortality, acute coronary syndromes and hospitalization in patients with coronary heart disease (CHD) and/or heart failure (HF). However, there is a paucity of randomized ...
Source: Cardiology - November 15, 2018 Category: Cardiology Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Major acute cardiovascular events after dengue infection –A population-based observational study
ConclusionsThe risks for MACEs are significantly higher in the immediate time period after dengue infection. Since dengue infection is potentially preventable by early recognition and vaccination, the dengue-associated MACE should be taken into consideration when making public health management policies.
Source: PLoS Neglected Tropical Diseases - February 7, 2022 Category: Tropical Medicine Authors: Kai-Che Wei Source Type: research

Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65  years: a systematic review
Geroscience. 2023 Jun 3. doi: 10.1007/s11357-023-00807-4. Online ahead of print.ABSTRACTThis systematic review aims to summarize the impact of vaccination against influenza, shingles, and pneumococcus on the incidence on the risk of cardiovascular events in the elderly. This protocol was developed in accordance with PRISMA guidelines. We conducted a literature search and identified all relevant articles published regarding the matter up to September 2022. We retrieved 38 studies (influenza vaccine = 33, pneumococcal vaccine = 5, and zoster vaccine = 2). A total of 28 and 2 studies have shown that influenza and pneumococcal...
Source: Herpes - June 3, 2023 Category: Infectious Diseases Authors: Alexandra Addario Thomas C élarier Bienvenu Bongue Nathalie Barth Ga ëtan Gavazzi Elisabeth Botelho-Nevers Source Type: research

A cluster randomized controlled trial comparing relative effectiveness of two licensed influenza vaccines in US nursing homes: Design and rationale.
CONCLUSIONS: This high-dose influenza vaccine trial uniquely offers a paradigm for future studies of clinical and programmatic interventions within the framework of efforts designed to test the impact of changes in usual treatment practices adopted by health care systems. TRIAL REGISTRATION: NCT01815268. PMID: 26908539 [PubMed - as supplied by publisher]
Source: Clinical Trials - February 11, 2016 Category: Research Authors: Gravenstein S, Dahal R, Gozalo PL, Davidson HE, Han LF, Taljaard M, Mor V Tags: Clin Trials Source Type: research

Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes.
Authors: Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, Millett C Abstract BACKGROUND: The health burden caused by seasonal influenza is substantial. We sought to examine the effectiveness of influenza vaccination against admission to hospital for acute cardiovascular and respiratory conditions and all-cause death in people with type 2 diabetes. METHODS: We conducted a retrospective cohort study using primary and secondary care data from the Clinical Practice Research Datalink in England, over a 7-year period between 2003/04 and 2009/10. We enrolled 124 503 adults with type 2 diabetes. Outcome me...
Source: Canadian Medical Association Journal - July 28, 2016 Category: Journals (General) Tags: CMAJ Source Type: research

Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis
CONCLUSIONS: Influenza vaccination appears to reduce adverse cardiovascular events, although the certainty of the evidence is low or very low. Rigorous randomized controlled trial evidence is needed to further examine the protective effect of the influenza vaccine in heart failure patients.PMID:35562195 | DOI:10.1016/j.vaccine.2022.04.039
Source: Vaccine - May 13, 2022 Category: Allergy & Immunology Authors: Christopher Gupta Anjali Sachdeva Jigish Khamar Cecilia Bu Jessica Bartoszko Mark Loeb Source Type: research

Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
Background As mortality from coronavirus disease 2019 (COVID-19) is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age-/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations. Methods We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including death, hospitalisation, intensive c...
Source: European Respiratory Review - November 2, 2022 Category: Respiratory Medicine Authors: Vardavas, C. I., Mathioudakis, A. G., Nikitara, K., Stamatelopoulos, K., Georgiopoulos, G., Phalkey, R., Leonardi-Bee, J., Fernandez, E., Carnicer-Pont, D., Vestbo, J., Semenza, J. C., Deogan, C., Suk, J. E., Kramarz, P., Lamb, F., Penttinen, P. Tags: Respiratory infections and tuberculosis Reviews Source Type: research